TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00819390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Taken orally, once daily, at a dose of 250 mg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken orally, once daily for 12 weeks.
Study: NCT02729753

Intervention type: DEVICE
Group type: OTHER
Intervention: CryoBalloon™ Full Ablation System
Description: Tissue Ablation using CryoBalloon™ Full Ablation System

Intervention type: DEVICE
Group type: OTHER
Intervention: CryoBalloon™ Swipe Ablation System
Description: Tissue Ablation using CryoBalloon™ Swipe Ablation System
Study: NCT04232059

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oximetry
Description: evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oximetry
Description: evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
Study: NCT04600492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat Oral Tablet
Description: Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riociguat Oral Tablet
Description: Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
Study: NCT03780075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.11GBq of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.00 GBq of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.70GBq of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT03897777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training effect on Hypertension and Gut Dysbiosis
Description: the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
Study: NCT05318313

Intervention type: OTHER
Intervention: Telerehabilitation
Description: The TR PT evaluation and follow-up visits will be performed via Zoom software

Intervention type: OTHER
Intervention: Telerehabilitation
Description: The TR PT evaluation and follow-up visits will be performed via Zoom software

Intervention type: OTHER
Intervention: Telerehabilitation
Description: The TR PT evaluation and follow-up visits will be performed via Zoom software
Study: NCT06591000

Intervention type: PROCEDURE
Intervention: tricuspid valve replacement
Description: Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis

Intervention type: PROCEDURE
Intervention: tricuspid valve replacement
Description: Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
Study: NCT03854773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group ESPB)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracal paravertebral block (Group TPVB)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group (group C)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT03770910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor antagonist
Description: GIP receptor antagonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor antagonist
Description: GIP receptor antagonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor antagonist
Description: GIP receptor antagonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor antagonist
Description: GIP receptor antagonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor agonist
Description: GIP(1-42)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor agonist
Description: GIP(1-42)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor agonist
Description: GIP(1-42)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor agonist
Description: GIP(1-42)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP receptor agonist
Description: GIP(1-42)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo (vehicle for infusions)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (vehicle for infusions)
Study: NCT00577837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: tablet, 5 mg risedronate daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: tablet, 100 mg risedronate monthly for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: tablet, 150 mg risedronate monthly for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental
Description: tablet, 200 mg risedronate monthly for 6 months
Study: NCT01018147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-dimensional computed tomography
Description: Undergo 4-D CT imaging
Study: NCT03299868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: peripherally inserted central catheter (PICC)
Description: comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripherally inserted central catheter (PICC)
Description: comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
Study: NCT02413333

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Plus contact lens solution
Description: 3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Plus contact lens solution
Description: 3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: PeroxiClear contact lens solution
Description: 3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: PeroxiClear contact lens solution
Description: 3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses
Description: 2-week/monthly replacement contact lenses per participant's habitual brand

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses
Description: 2-week/monthly replacement contact lenses per participant's habitual brand
Study: NCT04684407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROOT CANAL TREATMENT
Description: TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
Study: NCT00888004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02824419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methionine
Description: Subject undergoes imaging studies with FDG and with methionine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTANOC
Description: Subject undergoes imaging studies with FDG and with DOTANOC.
Study: NCT02220231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: capnothorax
Description: After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
Study: NCT03046654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans vaginal sonography
Description: Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal examination
Description: Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Speculum examination
Description: Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
Study: NCT02816242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concept map teaching
Description: teaching anatomy using concept map to improve critical thinking

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional teaching
Description: teaching anatomy using lecture
Study: NCT01976117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enose
Study: NCT00824447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: allergen solution sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: allergen solution sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: allergen solution sublingually

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study: NCT02865980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove extract
Description: in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove extract
Description: in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betadine
Description: in control group, will be washed the Catheter with Betadine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betadine
Description: in control group, will be washed the Catheter with Betadine
Study: NCT03816267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer
Description: Nebulization via mask

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Delivery of appropriate dose according to weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Delivery of appropriate dose according to weight

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler and spacer
Description: Medication will be delivered through inhaler and spacer
Study: NCT04310891

Intervention type: RADIATION
Intervention: Markerless Tumour Tracking
Description: Intrafraction Kolovoltage X-ray Imaging using Fiducials
Study: NCT02047864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Creatine monohydrate
Study: NCT05347420

Intervention type: DIAGNOSTIC_TEST
Intervention: The visual Neuropad test and the quantitative Neuropad test
Description: The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.

Intervention type: DIAGNOSTIC_TEST
Intervention: The visual Neuropad test and the quantitative Neuropad test
Description: The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
Study: NCT02865486

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
Study: NCT04555980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warming patch
Description: The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cotton patch
Description: The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
Study: NCT01140711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI imaging following visual stimulation of food and non-food images
Description: fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI imaging following visual stimulation of food and non-food images
Description: fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape.
Study: NCT02791074

Intervention type: OTHER
Intervention: NTproBNP
Description: To assess its level in the blood, as a marker of heart failure presence and severity.

Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.

Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.

Intervention type: OTHER
Intervention: Arterial tonometry
Description: A noninvasive method to obtain arterial pressure waveform.

Intervention type: OTHER
Intervention: Arterial tonometry
Description: A noninvasive method to obtain arterial pressure waveform.
Study: NCT03120247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTM Dexmedetomidine 1µg/ kg.
Description: Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTM Dexmedetomidine 0.75µg/ kg.
Description: Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTM Dexmedetomidine 0.5µg/ kg.
Description: Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
Study: NCT04555382

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and Urine
Description: Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and Urine
Description: Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
Study: NCT03945240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1 -- using Pinnacle Series Laser Device
Description: Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2 -- using Pinnacle Series Laser Device
Description: Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 3 -- using Phoenix Thera-Lase Device
Description: Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW
Study: NCT03579251

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Black Men's Care
Description: 12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
Study: NCT01130233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic assisted rectal resection
Description: robotic assisted rectal resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic rectal resection
Description: laparoscopic rectal resection